Details

Autor(en) / Beteiligte

• Tada, Toshifumi
• Kumada, Takashi
• Hiraoka, Atsushi
• Hirooka, Masashi
• Kariyama, Kazuya
• Tani, Joji
• Atsukawa, Masanori
• Takaguchi, Koichi
• Itobayashi, Ei
• Fukunishi, Shinya
• Tsuji, Kunihiko
• Ishikawa, Toru
• Tajiri, Kazuto
• Ochi, Hironori
• Yasuda, Satoshi
• Toyoda, Hidenori
• Ogawa, Chikara
• Nishimura, Takashi
• Hatanaka, Takeshi
• Kakizaki, Satoru
• Shimada, Noritomo
• Kawata, Kazuhito
• Tanaka, Takaaki
• Ohama, Hideko
• Nouso, Kazuhiro
• Morishita, Asahiro
• Tsutsui, Akemi
• Nagano, Takuya
• Itokawa, Norio
• Okubo, Tomomi
• Arai, Taeang
• Imai, Michitaka
• Naganuma, Atsushi
• Koizumi, Yohei
• Nakamura, Shinichiro
• Joko, Kouji
• Iijima, Hiroko
• Hiasa, Yoichi

Titel

Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis

Ist Teil von

• European journal of gastroenterology & hepatology, 2022-06, Vol.34 (6), p.698

Ort / Verlag

England

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). A total of 249 patients with unresectable HCC treated with Atez/Bev were included. We analyzed survival and discontinuation of this therapy in this cohort. Cumulative overall survival at 2, 4, 6, and 8 months was 97.6%, 94.9%, 88.9%, and 82.8%, respectively. Cumulative overall survival differed significantly between patients with low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative progression-free survival did not differ between patients with low versus high NLR. The distribution of response was 1.5% for complete response, 17.1% for partial response, 60.5% for stable disease, and 21.0% for progressive disease. Responses were not different between patients with low and high NLR. Regarding adverse events, immune-related liver injury of any grade and grade of at least 3, decreased appetite of any grade, grade of at least 3 proteinuria, and other adverse events of any grade differed significantly between patients with low and high NLR. There were 56, 18, and 2 patients who discontinued Atez/Bev therapy due to progression of disease, adverse event, and other reasons, respectively. The cumulative discontinuation rate for Atez/Bev therapy due to adverse events differed significantly between patients with low versus high NLR (P = 0.022). Cox proportional hazards modeling analysis with inverse probability weighting showed that NLR of at least 3.0 was significantly associated with overall survival (hazard ratio, 3.369; 95% confidence interval, 1.024-11.080). NLR can predict outcomes in patients with unresectable HCC treated with Atez/Bev.